• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Authors contribution br Corinne Calo DO


    Authors' contribution
    Corinne Calo, DO: Primary author. Performed majority of the chart review and wrote the bulk of the abstract/manuscript.
    John Elliott, MPH, PhD: Helped to organize data and performed ma-jority of statistical analyses.
    Gary Reid, MD: Provided charts for chart review, helped in writing and editing the abstract and final paper.
    Aine Clements, MD: Provided charts for chart review, helped in writ-ing and editing the abstract and final paper. Performed statistical analy-sis and created figures for progression free survival and overall survival.
    Kellie Rath, MD: Primary investigator/mentor for project. Helped to design the project and data collection sheet. Helped in writing and editing the abstract and final paper.
    There are no conflicts of interest to disclose.
    [3] R.M. Lanciano, M. Won, Coia Lr, et al., Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final re-port of the 1973 and 1978 patterns of care studies, Int. J. Radiat. Oncol. Biol. Phys. 20 (1991) 667–676. [4] Commission on Cancer's National Cancer Database. Cervix measure specifications ( 20specs%20cervix.ashx). [5] Foundation for women's cancer quality indicators ( [6] P.J. Eifel, A. Ho, N. Khalid, B. Erickson, J. Owen, Patterns of DPPH therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study, Int. J. Radiat. Oncol. Biol. Phys. 89 (2014) 249–256.
    [7] Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 random-ized trials, J. Clin. Oncol. 26 (2008) 5802–5812.
    Contents lists available at ScienceDirect
    Journal of Magnetism and Magnetic Materials
    journal homepage:
    Research articles
    Cetuximab and Doxorubicin loaded dextran-coated Fe3O4 magnetic T
    nanoparticles as novel targeted nanocarriers for non-small cell lung cancer
    Qinlu Zhanga, Qian Liub, Menghan Dub, Alphons Vermorkenb, Yali Cuib, Lixia Zhangc, Lili Guob, Le Mab, , Mingwei Chena, a First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China
    b National Engineering Research Center for Miniaturized Detection Systems, Northwest University, Xi'an 710069, PR China
    c Department of Clinical Laboratory, Shaanxi Provincial People's Hospital, Xi'an 710069, PR China
    Drug targeting
    Non-small cell lung cancer
    Epidermal growth factor receptor 
    Non-small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancer which is the leading cause of cancer death worldwide. Eighty percent of NSCLC patients exhibit high levels of epidermal growth factor receptor (EGFR) expression. In recent years, Doxorubicin (Dox, a widely used chemotherapeutic drug) and/or Cetuximab (Cet, an EGFR-targeted inhibitor) combined with nanoparticles for cancer therapy have attracted significant attention due to their efficient targeting and the resulting increased cytotoxicity on tumor cells. Herein, we report the effects of Dox and Cet, co-conjugated to dextran-coated Fe3O4 magnetic nanoparticles (Dox-NPs-Cet) on the NSCLC cell line A549, which expresses a high level of EGFR. Cytotoxicity, cell proliferation and inter-cellular uptake were investigated after treatment with this conjugate. The results indicate that Dox-NPs-Cet significantly suppress cell proliferation of A549 cells as compared with A549 cells treated with NPs only con-jugated with Dox. In summary, our study demonstrates that Dox-NPs-Cet could serve as a promising candidate for targeted therapy of NSCLC.
    1. Introduction
    Lung cancer is the most common cause of cancer-related death worldwide [1–3]. Two broad classes are distinguished: non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma. The three main subtypes of NSCLC are adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma. NSCLC is the most common form of lung cancer and nearly 85–90% of lung cancer patients are diagnosed as having NSCLC [4]. Depending on the stage of the tumor, the clinical treatment strategy for NSCLC patients may include surgery, radiation therapy and chemotherapy. Regrettably the majority of patients present with al-ready locally advanced or metastatic disease which limits the use of surgery to a minority of patients [5]. Chemotherapy is neither specific, nor selective and results in only a modest increase in survival while it involves significant toxicity for the patient [6]. These limitations of available systemic treatments for NSCLC emphasize the need for new approaches with improved efficacy and safety profiles [6].